# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070296
Filing Date
2025-05-13
Accepted
2025-05-13 16:05:31
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | stok-20250331.htm iXBRL | 10-Q | 2148991
2 | EX-10.1 | stok-ex10_1.htm | EX-10.1 | 41281
3 | EX-10.2 | stok-ex10_2.htm | EX-10.2 | 1209629
4 | EX-31.1 | stok-ex31_1.htm | EX-31.1 | 17882
5 | EX-31.2 | stok-ex31_2.htm | EX-31.2 | 17687
6 | EX-32.1 | stok-ex32_1.htm | EX-32.1 | 9437
7 | EX-32.2 | stok-ex32_2.htm | EX-32.2 | 10490
| Complete submission text file | 0000950170-25-070296.txt |  | 9145419

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | stok-20250331.xsd | EX-101.SCH | 902182
70 | EXTRACTED XBRL INSTANCE DOCUMENT | stok-20250331_htm.xml | XML | 1312985

Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38938 | Film No.: 25939964
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)